645-35-2

Basic information

• Product Name: L-Histidine hydrochloride
• Synonyms: monohydrochloride,l-histidin;HISTIDINE-L HCL;L-HISTIDINE HCL;L-(+)-HISTIDINE MONOHYDROCHLORIDE;L-HISTIDINE MONOHYDROCHLORIDE;L-Histidine hydrochloride;L-Histidine·hydrochloric acid;(-)-Histidine monohydrochloride
• CAS NO: 645-35-2
• Molecular Formula: C₆H₉N₃O₂*ClH
• Molecular Weight: 191.62
• EINECS: 211-438-9
• Product Categories: Amino Acids;Amino AcidsAlphabetic;Amino Acids, Peptides and Proteins;H;HA -HT;Life Sciences Standards
• Mol File: 645-35-2.mol

Chemical Properties

• Melting Point: 243-244 °C(Solv: ethanol (64-17-5))
• Boiling Point: 458.9 °C at 760 mmHg
• Flash Point: 231.3 °C
• Appearance: /Crystalline
• Density: 1.472[at 20℃]
• Vapor Pressure: 3.25E-09mmHg at 25°C
• Storage Temp.: 2-8°C
• Water Solubility: 149.55g/L at 20℃
• BRN: 4168261
• CAS DataBase Reference: L-Histidine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: L-Histidine hydrochloride(645-35-2)
• EPA Substance Registry System: L-Histidine hydrochloride(645-35-2)

Safety Data

• Safety Statements: 22-24/25:
• RIDADR: UN 1789 8/PG 3
• WGK Germany: 2
• F: 10
• Hazardous Substances Data: 645-35-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
L-Histidine hydrochloride is used as a supplement for addressing riboflavin vitamin deficiency, helping to improve overall health and well-being.
Used in Food Industry:
L-Histidine hydrochloride is used as an amino acid in the food industry, contributing to the essential amino acid content of various food products and supporting their nutritional value.
Used in Cosmetic Industry:
L-Histidine hydrochloride is used as a component in cosmetic formulations, where it may play a role in skin health and provide benefits such as moisturization and skin conditioning.
Used in Research and Development:
L-Histidine hydrochloride is utilized in research and development settings for studying its properties and potential applications in various fields, including pharmaceuticals, food, and cosmetics.

Flammability and Explosibility

Notclassified

InChI:InChI=1/C6H9N3O2.ClH/c7-5(6(10)11)1-4-2-8-3-9-4;/h2-3,5H,1,7H2,(H,8,9)(H,10,11);1H

Upstream product

• 6459-59-2 histidine hydrochloride 
• 71-00-1 L-histidine 
• 71-00-1 L-histidine 

Downstream Products

• 1499-46-3 L-Histidine methyl ester 
• 77504-36-0 2-amino-3-((4-((S)-2-amino-2-carboxyethyl)-1H-imidazol-2-yl)thio)propionic acid 
• 105158-70-1 2,5-diiodo-L-histidine ; hydrochloride 
• 6459-59-2 histidine hydrochloride 
• 2002-22-4 (2S)-2-amino-3-(2-mercapto-1H-imidazol-4-yl)propanoic acid 
• 24593-59-7 L-histidine benzyl ester di-para-toluene sulfonate 
• 25303-09-7 (RS),(S)-histopine 
• 20866-46-0 N,1'-bis[(1,1-dimethylethoxy)carbonyl]-L-histidine 
• 14997-58-1 N-[(benzyloxy)carbonyl]-L-histidine 
• 18502-05-1 4-cyanomethylimidazole 
• 2497-02-1 N-acetyl-L-histidine 
• 75614-87-8 (R)-2-(1H-Imidazol-4-yl)-1-methyl-ethylamine 
• 75614-85-6 (S)-(+)-4-(2-amino-3-chloropropyl)-imidazole dihydrochloride 
• 4836-52-6 (S)-histidinol 

Relevant articles and documents

Crystal studies, vibrational spectra and non-linear optical properties of l-histidine chloride monohydrate

This paper presents the results of our calculations on the geometric parameters, vibrational spectra and hyperpolarizability of a non-linear optical material l-histidine chloride monohydrate. Due to the lack of sufficiently precise information on geometri

Application of isotope-enriched 3-amino-1-propanesulfonic acid and derivative thereof

The present invention relates to the use of isotopically enriched compounds of general formula I or pharmaceutically acceptable salts or esters thereof, and corresponding pharmaceutical compositions for the prevention and treatment of cerebrovascular diseases and disorders, such as vascular dementia, cerebral apoplexy, and the like. In the formula (I), R1R2X-CR2-CH2-CH2-SO3H is shown in the specification.

Resolution of DL-racemic mixtures

The present invention relates to a process for the resolution of DL-racemic mixtures of compounds which crystalize in the form of a conglumerate. Both, the D and L-enantiomers are obtained according to the invention in a industrially feasable process by adding chiral enantioselective polymers to the supersaturated solution of the racemat to inhibit crystalization of one enantiomer. Next a DL-racemic mixture of said compound is suspended in about twice the amount of the crystallized enantiomer. Consequently, the opposite enantiomer could be recovered by said suspension by physical separation.

DESIGN OF STEREOSPECIFIC INHIBITORS FOR CRYSTAL DISSOLUTION

A new class of monomeric and polymeric crystal dissolution inhibitors has been prepared taking into consideration the packing arrangements and the morphologies of organic crystals.The efficiency of these inhibitors has been demonstrated by comparative morphological studies of α-glycine and by the kinetic resolution of the racemic conglomerates of his*HCl*H2O, threonine, glu*HCl, and 2,4-sec-phenetyl-3,5-dinitrobenzoate.